Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and WGS test for genome wide detection of DNA variants, including SNP, CNV, Indel, and SV. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. The company serves various organizations and facilities, including hospitals, research institutions, universities, and corporations. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.

Mr. Aoyang  Jia

Deputy General Manager

Ms. Wenlu  Ai

Secretary

Mr. Songqing  Zhang

Financial Director

Dr. Yang  Gao

GM & Chairman

Dr. Daixing  Zhou

Co-Founder & Chief Scientist

Biotechnologie

Berry Genomics Co.,Ltd

Berry Genomics Co.,Ltd Management-Struktur

Informationen zum Management